GSK re­vis­es Covid deal with Vir, pulls out of next-gen work

GSK is tak­ing an axe to an­oth­er of Hal Bar­ron’s lega­cy pacts, end­ing a col­lab­o­ra­tion with Vir Biotech­nol­o­gy work­ing on new an­ti­bod­ies and vac­cines against Covid-19.

The com­pa­nies aren’t cut­ting ties en­tire­ly; they will re­main al­lied on Xe­vudy (sotro­vimab) in mar­kets where it’s au­tho­rized, and an ex­per­i­men­tal “dual func­tion” Covid an­ti­body dubbed VIR-7832. GSK is al­so keep­ing its ex­pand­ed deal with Vir around ther­a­pies for in­fluen­za and oth­er res­pi­ra­to­ry dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER